Core Laboratories Inc.
CLB
$11.18
$0.211.91%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -104.78% | 236.65% | 26.88% | -60.47% | 35.69% |
| Total Depreciation and Amortization | -3.28% | -5.42% | -6.44% | -4.24% | -4.97% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -40.86% | -102.81% | -1,367.71% | 66.70% | -16.65% |
| Change in Net Operating Assets | 81.37% | 17.62% | 93.12% | 318.83% | 49.59% |
| Cash from Operations | 20.43% | 6.10% | 6,277.83% | 96.16% | 274.50% |
| Capital Expenditure | -17.27% | -60.12% | 21.15% | -31.83% | -38.22% |
| Sale of Property, Plant, and Equipment | 107.42% | 1,133.85% | 98.51% | -23.81% | 641.25% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 289.15% | -91.11% | 34,983.33% | -36.85% | 791.11% |
| Cash from Investing | 146.59% | -45.50% | 85.51% | -156.31% | 18.69% |
| Total Debt Issued | -7.14% | -50.00% | -79.75% | -90.80% | -41.67% |
| Total Debt Repaid | 11.76% | 25.93% | 71.08% | 75.29% | -6.25% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -4,495.45% | -174.89% | 10.09% | 18.59% | -4,300.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -0.21% | -0.43% | -0.43% | -0.43% | -0.43% |
| Other Financing Activities | 101.58% | 100.00% | 87.57% | 96.73% | 61.33% |
| Cash from Financing | -9.85% | -4.84% | -47.41% | -32,464.29% | -167.28% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,525.12% | -54.88% | 139.41% | -71.95% | -124.15% |